BioLife Solutions Stock (NASDAQ:BLFS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$26.10

52W Range

$17.86 - $29.62

50D Avg

$22.89

200D Avg

$23.96

Market Cap

$1.30B

Avg Vol (3M)

$518.09K

Beta

1.97

Div Yield

-

BLFS Company Profile


BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

159

IPO Date

Nov 22, 1989

Website

BLFS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Product$76.03M$117.69M-
Rental Revenue$6.07M$8.03M$4.63M
Service$160.00K$17.55M-
Service Revenue--$210.00K

Fiscal year ends in Dec 25 | Currency in USD

BLFS Financial Summary


Dec 25Dec 24Dec 23
Revenue$96.21M$82.25M$75.86M
Operating Income$-12.13M$-7.13M$-23.44M
Net Income$-12.13M$-20.18M$-66.43M
EBITDA$-12.13M$1.53M$-45.24M
Basic EPS$-0.25$-0.44$-1.52
Diluted EPS$-0.25$-0.44$-1.52

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 08, 26 | 12:00 AM
Q4 25Feb 26, 26 | 4:30 PM
Q3 25Nov 06, 25 | 4:30 PM

Peer Comparison


TickerCompany
KMTSKestra Medical Technologies, Ltd.
ESTAEstablishment Labs Holdings Inc.
PHRPhreesia, Inc.
HROWHarrow Health, Inc.
NEOGNeogen Corporation
ATRCAtriCure, Inc.
STAASTAAR Surgical Company
PLSEPulse Biosciences, Inc.
AZTAAzenta, Inc.
NVCRNovoCure Limited